Literature DB >> 22507753

Preserved autonomic function in patients with POEMS syndrome.

Y Fujinuma1, M Asahina, T Fukushima, A Katagiri, Y Yamanaka, S Misawa, S Kuwabara.   

Abstract

AIM: We systematically performed autonomic testing on patients with polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes syndrome (POEMS) to determine whether autonomic function is preserved in such patients.
METHODS: We studied 17 POEMS patients, 17 diabetic neuropathy (DN) patients and 17 age-matched normal subjects. Blood pressure responses to the head-up tilt test and heart rate variability were used to evaluate cardiovascular autonomic function. Sweat responses and cutaneous vasoconstriction to several stimuli were recorded via the finger tips to estimate cutaneous sympathetic function. In addition, motor nerve conduction studies were performed.
RESULTS: Although the results of the autonomic testing were normal in POEMS patients, motor disability was severe, and motor nerve conduction studies provided evidence of extensive axonal loss. The DN patients showed significantly impaired autonomic responses despite mild motor dysfunction.
CONCLUSIONS: Autonomic function was normal in POEMS patients, indicating the preservation of autonomic fibers and selective involvement of large fibers.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22507753     DOI: 10.1016/j.jns.2012.03.004

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  2 in total

1.  Prominent dysautonomia in a patient with POEMS syndrome.

Authors:  Sharda Thakral; Naoum P Issa; Alexandru C Barboi; John M Lee
Journal:  Clin Auton Res       Date:  2016-05-11       Impact factor: 4.435

2.  Improvement of sexual function in POEMS syndrome after combination therapy of Lenalidomide and dexamethasone.

Authors:  Hongbo Yang; Xufei Huang; Qianqian Cai; Chen Wang; Xinxin Cao; Daobin Zhou; Jian Li
Journal:  Orphanet J Rare Dis       Date:  2016-06-18       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.